Beta Drugs (NSE:BETA) EV-to-EBITDA : 18.36 (As of Jun. 05, 2024)

Beta Drugs EV-to-EBITDA Chart

Beta Drugs Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
EV-to-EBITDA		Get a 7-Day Free Trial					3.09	4.89	12.62	11.21	19.04

Beta Drugs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial														12.62	-	11.21	-	19.04

Competitive Comparison of Beta Drugs's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Drugs's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Beta Drugs's EV-to-EBITDA falls into.

Beta Drugs EV-to-EBITDA Calculation

Beta Drugs's EV-to-EBITDA for today is calculated as:

Beta Drugs's current Enterprise Value is ₹11,266 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹614 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs  (NSE:BETA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Beta Drugs's PE Ratio for today is calculated as:

Beta Drugs's share price for today is ₹1190.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹37.900.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Beta Drugs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Beta Drugs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Beta Drugs (NSE:BETA) Business Description